anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants recruited from the university community in the Southeast U.S. will participate in a randomized, double-blind, placebo-controlled interventional study for approximately 9 weeks following obtainment of informed consent. Two weeks prior to randomization participants will begin the pre-baseline period and complete daily and weekly questionnaires (physical activity and muscle soreness, bowel movements and gastrointestinal health, flu and cold symptoms). Visit 2 will occur during the pre-baseline period and participants will complete a VO2 max fitness assessment, which will be used during the endurance testing. Participants will also receive the SenseWear Armdand Mini®, a wearable device that will record their physical activity, sleeping patterns and energy expenditure for one week prior to visits 3 and 4.

Participants will be randomized at visit 3. Prior to this visit, participants will consume a standardized breakfast, collect a stool sample and a saliva sample that will be brought to site. During this visit participants will have a body composition and perform the Submaximal Treadmill Test. During the treadmill test, participants will provide finger prick samples for subsequent analysis of blood metabolites (glucose and lactate) and perceived exhaustion subjectively. Lastly, participants will complete several nutrition and motivation-related questionnaires.

One week prior to the final visit (V4), participants will be asked to wear the SenseWear Armband Mini® again for one week, which they will return at the final visit. Participants will eat another standardized breakfast prior to the final visit, visit 4. They will bring a stool and saliva sample to the site. During visit 4, participants will complete the submaximal treadmill test, while providing finger prick samples for analysis of blood and lactate levels. In addition, body composition will be assessed, as well as nutrition and motivation (subjectively). Visit 4 will be followed by a washout week, during which participants will not intake the study supplement but they will complete daily, weekly, and the final questionnaire.
FIELD: medicine. SUBSTANCE: the present innovation deals with correction of sensitive, motor and/or cognitive failure due to intracerebral transplantation of cells and, also, it deals with cells and medicinal preparation for implementing transplantation mentioned. It is presented the transplantation of hemopoietic stem cells for treating affected brain. Moreover, hemopoietic stem cell should be conditionally immortalized, it could include temperature-sensitive oncogen which is not expressed at 35 C, and higher and expresses T-antigen SV40. Hemopoietic stem cell could be genetically transformed for expression of therapeutic heterologous gene product. Thus, the suggested transplantation of hemopoietic stem cells could be applied for treating Alzheimer's disease, Parkinson disease and that of Creutzfeldt-Jakob. EFFECT: higher efficiency of transplantation. 12 cl
Critically ill pediatric patients supported on ventricular assist devices (VADs) are increasingly being anticoagulated on bivalirudin, but with difficulty monitoring anticoagulation. Activated partial thromboplastin time (aPTT) has recently been shown to poorly correlate with bivalirudin plasma concentrations, while dTT had excellent correlation. However, aPTT is the more common monitoring test and dTT testing is rarely used. In addition, effects of frequent clinical VAD scenarios (such as inflammation) on the accuracy of aPTT and dTT testing remains uncertain. We reviewed the effects of clinical scenarios (infection/inflammation, chylothorax, and steroids administration) on anticoagulation monitoring in 10 pediatric VAD patients less than 3 years at Cincinnati Children's Hospital Medical Center from 10/27/2020 to 5/6/2022 using bivalirudin for anticoagulation. There were 16 inflammation/infection, 3 chylothorax, and 6 steroids events. Correlation between dTT and aPTT was significantly lower after infection/inflammation, with dTT increasing prior to inflammation/infection while aPTT remained unchanged. In addition, steroids are administered to VAD patients to reduce inflammation and thus additionally stabilize anticoagulation. However, this anticoagulation stabilization effect was reflected more accurately by dTT compared to aPTT. In children requiring VAD support utilizing bivalirudin anticoagulation, inflammation/infection is a common occurrence resulting in anticoagulation changes that may be more accurately reflected by dTT as opposed to aPTT.
<P>PROBLEM TO BE SOLVED: To provide a new complex used for administering a functional substance such as a drug into a living body, simply preparable and having even good biocompatibility.  <P>SOLUTION: The complex is composed of the functional substance having a cationic site (e.g. an antitumor agent such as doxorubicin), an anionic water-soluble polymer (e.g. γ- or α-polyglutamic acid) and an amphiphilic compound having a cationic group at the molecular terminal (e.g. a quaternary ammonium type lipid) and sustainedly releases the functional substance. The complex is obtained by stirring and mixing an aqueous solution containing the functional substance having the cationic site, the anionic water-soluble polymer and the amphiphilic compound having the cationic group at the molecular terminal and then carrying out an ultrasonic treatment.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Intragastric administration of a quinine-solution has shown to decrease hedonic food intake in healthy female volunteers. The effect of a tablet containing hydroxychloroquine sulphate on hedonic food intake in overweight female individuals has not been studied to date. The primary outcome of the current study is to evaluate the effect of hydroxychloroquine sulphate on hedonic food intake, assessed by ad libitum food intake of a chocolate milkshake one hour after dosing. The study is a randomized, placebo-controlled, double blinded cross-over study. Forty overweight females will be recruited. An acute dose of 400 mg hydroxychloroquine sulphate will be administered. Blood samples will be collected at regular time points to measure gastrointestinal hormone release and whole blood glucose levels. Appetite-related sensations will be scored at regular time points on visual analog scales.
The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed. The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed. A surgical instrument includes a handpiece having a user input feature and a user feedback feature. A shaft assembly extends distally from the handpiece. An end effector is disposed at a distal end of the shaft assembly. The end effector includes an active feature responsive to actuation of the user input feature. The active feature is operable to operate on tissue in response to actuation of the user input feature. The user feedback feature is operable to provide feedback to the user that indicates information relating to operation of the end effector. The feedback may include haptic, visual, and/or auditory feedback.
FIELD: organic chemistry, medicine, pharmacy. SUBSTANCE: application of compound of the formula (I)   wherein R means optionally substituted linear or branched carbon chain with 12-22 carbon atoms that can be broken optionally by substituted phenylene; each among R 2 , R 3 , R 4 , R 5  independently each of other means hydrogen atom or lower alkyl in free form or in the form of pharmaceutically acceptable salt for prophylaxis or treatment of chronic rejection of allograft or xenotransplant of organ or tissue in recipient or acute rejection of xenotransplant in recipient. Invention relates to pharmaceutical and therapeutic composition containing these compounds. Invention allows the realization of indicated designation. EFFECT: valuable medicinal properties of derivatives and compositions. 7 cl, 1 ex
The International Agency for Research on Cancer has classified the consumption of heat-processed meat as a direct human carcinogen and the consumption of red meat as a probable carcinogen. Mutagenic and carcinogenic compounds present in meat dishes include, among others, polycyclic aromatic hydrocarbons (PAHs) and heterocyclic aromatic amines (HAAs). These compounds can cause the development of gastrointestinal cancer. Oral cancer is one of the world's research priorities due to the ever-increasing incidence rate. However, the effect of diet on oral cancer is still a poorly recognized issue. The aim of this study was to assess the relationship between the risk of oral cancer and dietary ingredients with a particular emphasis on red meat and thermally processed meat. This study was conducted among patients with oral cancer in 2022 and 2023. The shortened standardized Food Frequency Questionnaire (FFQ) and a multivariate regression statistical analysis were used. The high consumption of red meat in general and thermally processed meat, especially smoked, fried, roasted and boiled, increases the risk of oral cavity cancer. Limiting the consumption of meat products and modifying the methods of preparing meat dishes may reduce exposure to carcinogenic compounds from the diet and thus reduce the risk of developing oral cancer.
PURPOSE:To form a microcapsule only by means of adding the title composition into a liq. by preparing a composition for microcapsules with emulsifiers not reacting with each other and a compd. forming a coating film by the reaction with water as the essential components. CONSTITUTION:The emulsifiers not reacting with each other, the compd. forming a coating film by the reaction with water, and a component to be microcapsuled are mixed as the essential components to prepare the composition for microcapsules. The composition and water are mixed, and agitated to produce a microcapsule. Anionic, cationic, and nonionic surfactants can be exemplified as the emulsifier. A diisocyanate, a polyisocyanate, a urethane prepolymer, etc., are exemplified as the compd. forming a coating film by the reaction with water.
The waveforms of airway pressure (Paw), esophageal pressure (Pes), and transpulmonary pressure (Ptp) will be visualized on the ventilator. Ptp is obtained from Paw - Pes. PEEP will be increased on the ventilator to achieve a Ptp between 0 and +2 cm H2O (Optimal PEEP). Measurements will be obtained daily and adjustments to PEEP will occur daily. PEEP will be reduced below Optimal PEEP in the setting of hemodynamic compromise (requiring increasing vasoactive medications for blood pressure support).
Includes one online, single-session program, the Self-Kindness Program. The 30-minute, self-administered youth program includes: An introduction to the science behind why adolescents might think disliking themselves is necessary for success and thus fear self-compassion; Scientific evidence and testimonials from other teens that being self-compassionate actually predicts being more successful socially and academically; Evidence-based tips for overcoming common, fear of self-compassion based obstacles to self-compassion in day to day life; And an exercise in which youths write notes to younger students, using scientific information to explain the benefits of using self-kindness.
Fendrix (Hepatitis B surface antigen adjuvanted by AS04C containing 3¬≠O¬≠desacyl¬≠4'¬≠ monophosphoryl lipid A adsorbed on aluminium phosphate, GlaxoSmithKline; 0.5 mL. intramuscular. stat.
ACTOPLUS MET tablets are a thiazolidinediones and biguanide combination product that contains two oral antidiabetic medications: pioglitazone HCl and metformin HCl.

Pioglitazone [(±)-5-[[4-[2-(5-ethyl-2-pyridinyl) ethoxy]phenyl]methyl]-2,4-] thiazolidinedione monohydrochloride contains one asymmetric carbon, and the compound is synthesized and used as the racemic mixture. The two enantiomers of pioglitazone interconvert in vivo. No differences were found in the pharmacologic activity between the two enantiomers. The structural formula is as shown:

Pioglitazone HCl is an odorless white crystalline powder that has a molecular formula of C19H20N2O3S•HCl and a molecular weight of 392.90 daltons. It is soluble in N,N-dimethylformamide, slightly soluble in anhydrous ethanol, very slightly soluble in acetone and acetonitrile, practically insoluble in water, and insoluble in ether.

Metformin HCl (N,N-dimethylimidodicarbonimidic diamide HCl) is a white crystalline powder with a molecular formula of C4H11N5•HCl and a molecular weight of 165.62. Metformin HCl is freely soluble in water and is practically insoluble in acetone, ether, and chloroform. The pKa of metformin is 12.4. The pH of a 1% aqueous solution of metformin HCl is 6.68. The structural formula is as shown:

ACTOPLUS MET is available as a tablet for oral administration containing 15 mg pioglitazone (as the base) with 850 mg metformin HCl (15 mg/850 mg) formulated with the following excipients: povidone USP, microcrystalline cellulose NF, croscarmellose sodium NF, magnesium stearate NF, hypromellose 2910 USP, polyethylene glycol 8000 NF, titanium dioxide USP, and talc USP.
Consecutive adult patients who underwent pain management at a Canadian pain clinic. The patients were subsequently prescribed and provided zopiclone 3.75mg tablet (1-2 tablets per dose), and clonidine 0.1mg tablet (1-2 tablets per dose). They were advised to take either clonidine or zopiclone on alternate nights. For each medication, they alternated the doses of 1 tablet or 2 tablets at subsequent nightly administrations. The four possible medication doses were zopiclone 3.75mg, zopiclone 7.5mg, clonidine 0.1mg, and clonidine 0.2mg; as shown on the sleep diary in Figure 1. The recommended orders of treatment were zopiclone 7.5mg, clonidine 0.1mg, zopiclone 3.75mg, clonidine 0.2mg; or clonidine 0.2mg, zopiclone 3.75mg, clonidine 0.1mg, zopiclone 7.5mg. Each patient participated in the study treatment and completed the sleep diary for 3 continuous weeks. Therefore, each of the four medication doses was used five times by each patient.
Active, non-invasive, alternating current transcutaneous stimulation through electrodes placed transcranially on the mastoid regions. Treatment is self-administered, with participant control of device output level and duration according to perceived benefit. Minimum treatment duration is one-hour, with self-administered extension not to exceed 7 days.
PURPOSE OF REVIEW: To discuss the recent discoveries and limitations of the available literature on emerging circulating biomarkers of cancer cachexia.
RECENT FINDINGS: Studies on circulating factors in cancer cachexia show promising alternatives for diagnosing the syndrome in a minimally invasive manner in the clinic setting, as well as potential targets for cancer cachexia treatment. Factors secreted by the tumor and the adipose tissue, such as extracellular vesicles and soluble proteins, respectively, have been shown to either directly induce wasting in vitro and in vivo or to be altered in the cachectic phenotype. The detection and characterization of circulating cells allows detection of the precachectic stage and the levels of the soluble immune checkpoint protein programmed death ligand-1 (PD-L1) are correlated with the presence of the hallmarks of cancer cachexia.
SUMMARY: Structural, molecular, and metabolic alterations have been observed in various tissues, revealing the occurrence of sustained inter-compartment crosstalk in cachectic patients. Early diagnosis of cancer cachexia becomes crucial to avoid the establishment of refractory cachexia through the implementation of interventions that may attenuate systemic inflammation and muscle loss. More studies on human cancer cachexia are required in order to address the recently discovered cachexia-associated circulating factors' value as biomarkers of the syndrome.
BACKGROUND:

Among patients with advanced CKD, cardiovascular disease is the leading cause of death,15-30 times higher than the age-adjusted cardiovascular mortality rate in the general population. The projected 4-year mortality is \>50% in patients with advanced CKD and is worse than that for patients in the general population who have cancers, heart failure, stroke or MI. Participants with advanced CKD are 5-10 times more likely to die than to reach end stage renal disease (ESRD). Despite this, \~80% of contemporary coronary artery disease (CAD) trials exclude participants with advanced CKD. Most of the treatments aimed at reducing cardiovascular events in advanced CKD are therefore extrapolated from cohorts without advanced CKD. Participants with advanced CKD and cardiovascular disease are undertreated with less frequent use of statins and revascularization therapies, and the optimal management approach to these patients is unknown. Participants with advanced CKD are notably underrepresented in contemporary trials comparing revascularization with medical therapy in SIHD patients, such as the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial or the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial,making any assessment about the efficacy of revascularization plus medical therapy vs. initial medical therapy alone in this cohort problematic.

Participants with advanced CKD are at increased risk for complications of the assigned invasive procedure, specifically contrast-induced acute kidney injury (AKI), dialysis, major bleeding and short-term risk of death. However, there is controversy in the medical literature regarding the incidence (\<1% to \>30%), effective treatment (saline hydration, N-acetyl cysteine, or sodium bicarbonate), and prognosis of contrast induced AKI (\<0.5% to \>5% requiring dialysis). In addition, although contrast induced AKI have been associated with increase in short-term mortality, residual confounding in these studies makes interpretation difficulty. Moreover, it is unknown if these short-term increased risks are offset by long-term benefits. Limited observational studies in the CKD cohort suggest a long-term survival benefit of revascularization when compared with medical therapy alone, despite an increase in short-term risks. However, the medical therapy in these trials was not optimized, drug eluting stents were rarely used and there is undoubtedly inherent selection and ascertainment bias with observational studies. The above has resulted in clinical equipoise in the management of these patients, with the rates of revascularization only around 10-45%. The results of ISCHEMIA-CKD will have profound implications for guidelines, health policy, and clinical practice.
Composition obtained from lysates of probiotic microorganisms for use in the treatment and/or prevention of degenerative eye diseases. The present invention refers to a composition for oral administration to prevent and treat degenerative eye diseases characterized in that it comprises lysates of probiotic microorganisms in the form of dry powder. In a second aspect, the invention refers to the use of the composition object of the invention as a food supplement for the prevention and/or delay of degenerative eye diseases. In a third aspect, the invention relates to the composition according to the first aspect for use as a medicine. In a fourth aspect, the invention relates to the composition according to the first aspect for use in the treatment of degenerative diseases of the eye. And in a final aspect, the invention relates to a pharmaceutical composition comprising a pharmaceutically effective amount of the composition according to the first aspect of the invention and a pharmaceutically acceptable excipient.  (Machine-translation by Google Translate, not legally binding)
BACKGROUND This study aimed to develop a predictive model for the association between maternal and neonatal anthropometric data and neonatal hypoglycemia based on data from mothers with gestational diabetes mellitus (GDM) and their neonates. MATERIAL AND METHODS We included 106 pregnant women with GDM (based on the World Health Organization International Association of Diabetes and Pregnancy Study Groups) and their neonates. Neonatal hypoglycemia was defined as a threshold of 2.5 mmol/L. Neonatal blood glucose levels were performed at 0, 0.5, 1, 3, and 24 h after birth. An artificial neural network (ANN) and recurrent neural network (RNN) were developed to predict the neonate blood concentrations and investigate the relative contribution of maternal and neonate clinical variables to neonatal hypoglycemia. RESULTS Of 106 mothers with GDM, 85% had obesity, and 78% had vaginal deliveries, with neonates averaging a birth weight of 3335.83 g. The ANN model, based on the clinical data from mothers and neonates, predicted blood glucose levels with a high degree of accuracy, achieving a coefficient of determination of 0.869 and a root mean square error (RMSE) of 0.274. Neonatal birth weight and maternal body mass index were the 2 most significant factors in predicting neonatal hypoglycemia, contributing 18.6% and 15.9%, respectively. The RNN model similarly forecasted glucose levels effectively, addressing the dynamic changes in blood glucose with 0.63 mmol/L RMSE and 0.53 mmol/L mean absolute error. CONCLUSIONS ANN and RNN models effectively predict neonatal hypoglycemia in infants of mothers with GDM, highlighting the critical role of maternal and neonatal factors.
Capillary glucose level is measured using finger stick method by 4 times (fasting plus post-meals) every other day. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively.
Patients with ARDS who require mechanical ventilation after adequate disease assessment and whose heart rate continues to be ≥95 beats/min, but ≤120 beats/min within 24 hours after diagnosis, for at least 10 minutes without changing the dosage of catecholamine, were diagnosed as atrial fibrillation, atrial flutter or sinus tachycardia. The primary treatment is maintained while the esmolol load dose is administered and the maintenance dose is pumped continuously until the patient's heart rate is maintained between 80 and 94 beats per minute.
Participants will receive automated 'CareConnect' calls/SMS text at enrollment. The call protocol will include up to 2 calls on 2 consecutive days if no response to the first call. If there is no response to call, a follow up SMS 3-4 days later. Each CareConnect contact will include (1) assessment, (2) motivational enhancement tailored to participants' tobacco use status and importance of quitting; and (3) multiple referral options (UCSF Fontana Tobacco Treatment Center (FTTC)/tobacco treatment specialist, Quitline, or smokefreeTXT from smokefree.gov), offered after the motivational enhancement message. CareConnect will notify the UCSF tobacco treatment specialist of participants acceptance of any of the referral options. Referral options will be documented by the specialist on the participants electronic health record (EHR). All participants who have completed the CareConnect call will be contacted by research staff for a 3-month survey to be completed online or by telephone.